Hypera S.A. (BOVESPA:HYPE3) signed an agreement to acquire 12 Drugs Brands of Sanofi (ENXTPA:SAN) for approximately $190 million on July 13, 2021. As a part of acquisition, the agreement also includes four prescription products from the General Medicine portfolio. Sanofi does not anticipate any impact of this divestiture to its Latin American-based workforce.

The amount paid by Hypera was four times the turnover of these drugs and five times the Ebitda of R$165mil. The transaction is subject to approval of relevant regulatory authorities, approval by the competent antitrust authorities and other customary closing conditions. The transaction is expected to close at the end of 2021.

María Luisa Cánovas of Jones Day (France) acted as legal advisor to Sanofi. As of March 14, 2022, The Administrative Council for Economic Defence has approved acquisition of medicine portfolio of Sanofi by Hypera S.A.